October 16, 2024 | 3 months ago

Medicines: Saidal signs contract with Palestinian laboratory Beit Jala

On Wednesday, Saidal press release announced that the national pharmaceutical group signed a contract with the Palestinian pharmaceutical laboratory Beit Jala Pharmaceutical (Algeria), to produce several medicines.

Algeria Invest
Legal Notices | Terms of Services
news-detail

Wassim Kouidri, CEO of the Saidal Group, and Falastine Abou Nasr, General Manager of the Palestinian company, signed the contract.

In its press release, Saidal recalls that Beit Jala was founded in 1935 and has grown from a pharmacy to a pharmaceutical laboratory producing over 220 products covering several pharmaceutical categories.

Both parties expressed their ambition to start production as soon as possible to meet the local market before turning to exports to foreign countries, particularly in Africa.

The contract was signed following the June 25 meeting between the Minister of Industry and Pharmaceutical Production and the CEO of the Palestinian laboratory.

On that occasion, Aoun announced, as a reminder, that he would grant “all facilities to the Beit Jala laboratories, notably drug registration, the signing of agreements with the various laboratories and the manufacture of certain drugs in demand on the Algerian and Palestinian markets”.

October 17, 2024 | algeria-logo